Obstructive Jaundice Patient for Whipple Surgery

1. Introduction

2. Pathophysiology of Obstructive Jaundice Relevant to Surgery

• Current Surgical Therapy 14e (obstructive jaundice chapter): cholestasis impairs clotting and immunologic responses.
• Pye's Surgical Handicraft: coagulation defects in jaundice involve prothrombin, factor V, factor VII; a good response to IV vitamin K confirms posthepatic (surgical) jaundice.

3. Causes Requiring Whipple Surgery

• Carcinoma of the head of pancreas (most common)
• Distal cholangiocarcinoma (below the cystic duct junction)
• Ampullary carcinoma
• Duodenal carcinoma

• Chronic pancreatitis with head mass lesion
• Pseudotumoral chronic pancreatitis

4. Clinical Presentation

• Progressive, painless jaundice - classic feature of malignancy (fluctuating jaundice suggests stones)
• Dark urine, clay-coloured stools, pruritus, fatigue
• Courvoisier's sign - palpable, non-tender, distended gallbladder (total bilirubin >10 mg/dL is highly suggestive of malignancy)
• Weight loss, anorexia, nausea
• Fever if cholangitis is present

5. Preoperative Investigations

Biochemical

• LFTs: elevated bilirubin (predominantly direct), ALP (3-4x elevation in 75% of cholestasis), GGT, 5'-nucleotidase
• PT/INR, aPTT (assess coagulopathy)
• Serum albumin (nutritional status)
• Blood sugar (pre-existing or new-onset diabetes)
• Urea, creatinine (renal function baseline)
• FBC (anaemia, leucocytosis)
• Tumour markers: CA 19-9 (pancreatic/biliary malignancy), CEA
• Serum IgG4 (if autoimmune pancreatitis suspected)

Imaging

• Abdominal ultrasound - first-line; shows biliary dilation, level of obstruction, distended gallbladder
• CT (triple-phase: arterial, portal venous, pancreatic phase) - defines tumour extent, vascular involvement (SMA, SMV, PV, coeliac axis), lymphadenopathy, and distant metastases. Key for resectability assessment
• MRCP - excellent non-invasive imaging of biliary and pancreatic ducts; sensitivity 95% for biliary obstruction; differentiates benign from malignant strictures
• EUS (endoscopic ultrasound) - detects tumours at hilum, ampullary region, pancreatic head; guides fine-needle aspiration (FNA); sensitivity 84-91%, specificity 71-100% for distal biliary strictures
• ERCP - therapeutic (stenting) rather than primarily diagnostic; useful in cholangitis or severe hepatic congestion
• Chest CT - excludes pulmonary/mediastinal metastases
• Diagnostic laparoscopy - selectively used in high CA 19-9 or equivocal lesions to exclude occult metastases before laparotomy

Resectability Assessment (CT Criteria)

• Resectable: no arterial contact, <180° venous contact with SMV/PV
• Borderline resectable: >180° venous contact, <180° arterial contact
• Locally advanced/unresectable: >180° arterial contact (SMA/coeliac), complete venous occlusion

6. Preoperative Optimisation

Correction of Coagulopathy

• IV Vitamin K (10 mg daily for 3 days) - corrects PT if hepatocellular function is intact (confirming surgical jaundice)
• Fresh frozen plasma if urgent correction needed
• Check response: normalisation of PT indicates adequate hepatocyte synthetic function

Nutritional Optimisation

• High-protein, high-calorie diet
• Consider nasojejunal or parenteral nutrition if severely malnourished
• Correct hypoalbuminaemia

Renal Protection

• Adequate hydration/IV fluids preoperatively
• Mannitol infusion during surgery (renal protection against hepatorenal syndrome)
• Avoid nephrotoxic drugs

Preoperative Biliary Drainage

• Controversial - routine preoperative biliary stenting is NOT recommended
• Randomised controlled trial data (Maingot's; Current Surgical Therapy 14e) shows routine preoperative stenting in patients undergoing pancreaticoduodenectomy is associated with increased perioperative morbidity, especially infectious complications (bile contamination)
• Selective indications for biliary drainage (ERCP/stent or PTC):
  • Cholangitis - urgent drainage needed
  • Severe hepatic congestion/derangement
  • Significant delay until surgery (e.g., awaiting neoadjuvant therapy)
  • Bilirubin very high (>15 mg/dL) with planned delay >2 weeks
• Metallic stents are preferred over plastic if stenting is done before pancreaticoduodenectomy

Other

• Antibiotic prophylaxis (preoperative, broad-spectrum)
• DVT prophylaxis (subcutaneous heparin before induction)
• Cardiac and pulmonary evaluation (ECG, echo, PFTs as indicated)
• Optimise blood sugar
• Cross-match blood products

7. The Whipple Procedure (Pancreaticoduodenectomy)

Anatomy Removed

• Head, neck, and uncinate process of the pancreas
• Duodenum (entire)
• Distal stomach (antrum) in classic Whipple; preserved in pylorus-preserving variant (PPPD)
• Gallbladder
• Distal common bile duct
• Regional lymph nodes (aiming for ≥12 nodes)

Surgical Steps (Open Approach)

• Identify and divide the gastroduodenal artery (GDA) after confirming adequate hepatic arterial perfusion
• Skeletonise the portal vein (PV) and superior mesenteric vein (SMV) tunnel behind the pancreatic neck
• Cholecystectomy (top-down); divide CBD above cystic duct junction; bile cultures obtained

• Classic Whipple: antrectomy (gastrojejunostomy reconstruction later)
• Pylorus-preserving (PPPD): divide duodenum 2-3 cm distal to pylorus (duodenojejunostomy later)

Reconstruction (Child's Sequence)

1. Pancreaticojejunostomy (PJ) - pancreatic remnant anastomosed end-to-side to jejunum (duct-to-mucosa technique preferred); most critical anastomosis
2. Hepaticojejunostomy/Choledochojejunostomy (CJ) - bile duct anastomosed end-to-side to jejunum, 10-15 cm downstream from PJ
3. Gastrojejunostomy (GJ) or Duodenojejunostomy - antrum/pylorus anastomosed further downstream, completing reconstruction

8. Postoperative Complications (ISGPS-Defined)

Procedure-Specific Complications

• Most feared complication; incidence ~15%; responsible for 36% of mortality after PD
• Defined as: drain amylase >3x upper limit of normal on/after POD 3 + clinical impact
• Risk factors (Fistula Risk Score): soft gland texture, small duct (<3 mm), pathology other than pancreatic cancer/pancreatitis, high intraoperative blood loss
• Management: prolonged drainage, octreotide, nil by mouth, TPN; interventional radiology drainage; rarely re-operation

• Inability to tolerate oral intake by POD 7 or nasogastric tube in situ beyond POD 3
• Grade A/B/C based on clinical impact
• Management: nasogastric decompression, prokinetics (metoclopramide, erythromycin), parenteral nutrition

• Early (<24h): surgical bleeding from anastomosis or vessels
• Late (>24h): often sentinel bleed from pseudoaneurysm of GDA stump (alarming)
• Management: early - re-operation; late - CT angiography and interventional radiology embolisation

• From hepaticojejunostomy or cystic duct stump
• Management: ERCP and stenting, percutaneous drainage

• Lymphorrhea from lymphatic channels
• Management: low-fat/medium-chain triglyceride diet, octreotide

General Complications

• Surgical site infection (deep/superficial)
• Pneumonia
• DVT/PE
• Acute kidney injury
• Hepatic failure (particularly in severely jaundiced patients)
• Wound dehiscence

9. Perioperative Care

• ICU/HDU for at least 24-48 hours
• Arterial line - continuous BP monitoring intraoperatively
• Goal-directed fluid resuscitation - avoid over- or under-hydration
• Central venous access - avoid left neck if venous resection anticipated (left IJV may be needed as conduit)
• Drains - closed-suction abdominal drains placed near the pancreatic and biliary anastomoses; output monitored for amylase on POD 3 to detect fistula
• Nasogastric tube - early removal encouraged in PPPD
• Early enteral nutrition preferred when tolerated
• DVT prophylaxis - LMWH + compression stockings
• Perioperative antibiotics - redosed intraoperatively at appropriate intervals
• Blood glucose monitoring - newly or worsened diabetes common

10. Prognosis

• R0 (margin-negative) resection is the single most important prognostic factor
• Adjuvant chemotherapy (gemcitabine + capecitabine; or FOLFIRINOX) is standard after PD for pancreatic cancer
• Neoadjuvant therapy is increasingly preferred to improve R0 rates and select against rapid progressors

Summary Table

Anaesthetic Management of a Patient with Obstructive Jaundice for Whipple Surgery (Pancreaticoduodenectomy)

1. Introduction

2. Pathophysiological Effects of Obstructive Jaundice Relevant to Anaesthesia

3. Preoperative Anaesthetic Assessment

History

• Duration and depth of jaundice (total bilirubin level)
• Presence of pruritus, cholangitis (fever, rigors - Charcot's triad)
• Comorbidities: diabetes, cardiovascular disease, renal disease
• Drug history (NSAIDs, anticoagulants, hepatotoxins)
• Prior surgeries and anaesthetic history

Examination

• Jaundice, scratch marks (pruritus)
• Signs of malnutrition (muscle wasting, cachexia)
• Cardiovascular: bradycardia, peripheral vasodilation, volume status
• Ascites (not common in obstructive, unlike cirrhotic - but may be present with malignancy)
• Airway assessment (routine Mallampati, neck mobility)

Investigations

• FBC - anaemia, leucocytosis (cholangitis/infection)
• PT/INR, aPTT - critical for epidural decision and bleeding risk
• Platelet count
• Group and cross-match (2-4 units RBC, FFP, platelets)

• Bilirubin (total and direct), ALT, AST, ALP, GGT
• Serum albumin (below 3.5 g/dL = significant nutritional deficit)
• Urea, creatinine, electrolytes (Na+, K+, Mg2+) - baseline renal function
• Blood glucose (diabetes or new-onset in pancreatic disease)
• Ca 19-9, CEA (for oncological context)

• ECG (bradycardia, QT prolongation)
• Echocardiography if significant cardiac history or poor functional capacity

• CXR, pulse oximetry
• PFTs if clinically indicated
• ABG if hypoxaemia suspected

• CT/MRI reviewed for vascular anatomy (crucial for expected blood loss and vessel injury planning)

Risk Stratification

• Child-Pugh score (if hepatocellular component suspected): Class A acceptable, Class C contraindicates elective surgery
• MELD score: MELD <11 = low postoperative mortality; MELD ≥20 = high risk
• SORT/ASA score: Most patients are ASA III or IV

4. Preoperative Optimisation

Correction of Coagulopathy

• IV Vitamin K 10 mg daily x 3 days - corrects PT if hepatocyte synthesis intact (this also confirms the jaundice is obstructive, not hepatocellular - a positive response to Vitamin K = surgical jaundice)
• FFP/cryoprecipitate if urgent surgery or non-responsive to Vitamin K
• Target INR <1.5 before epidural placement
• Platelet transfusion if count <80,000/μL (for neuraxial anaesthesia)

Renal Protection

• Adequate IV hydration preoperatively
• Mannitol 0.5 g/kg IV given perioperatively - osmotic diuresis, free radical scavenging, renal protection
• Avoid NSAIDs, aminoglycosides, contrast agents
• Baseline creatinine documented; urine output targets set

Nutritional

• High-protein supplementation
• TPN if severely malnourished (albumin <2.5 g/dL) - start 7-10 days preoperatively
• Correct electrolytes (K+, Mg2+, glucose)

Biliary Drainage (Anaesthetic Perspective)

• If biliary stenting is performed: contaminated bile = higher risk of infectious complications intraoperatively
• Metal stents preferred over plastic if decompression is done before Whipple
• Routine preoperative stenting is NOT recommended - increases infection risk without improving mortality (Maingot's; Current Surgical Therapy)
• Exception: cholangitis, very high bilirubin with planned delay, or need for neoadjuvant therapy

Blood Bank Preparation

• Cross-match 4 units packed RBC, 4 units FFP, 1 adult dose platelets
• Cell salvage (autologous blood recovery) may be used if no malignancy spillage risk
• Discuss with surgeon expected blood loss (can be 500-2000 mL)

5. Choice of Anaesthetic Technique

General Anaesthesia + Thoracic Epidural: Gold Standard

• Excellent intraoperative and postoperative analgesia
• Reduces stress response and sympathetic activation (preserves hepatic blood flow)
• Decreases intraoperative opioid requirements (less hepatic metabolism burden)
• Reduces postoperative pulmonary complications (especially important in long procedure)
• Facilitates early extubation and ambulation (ERAS protocol)
• Associated with reduced postoperative ileus (sympathetic block promotes gut motility)

• Uncorrected coagulopathy (INR >1.5, platelets <80,000)
• Patient refusal or sepsis/bacteraemia
• If contraindicated: TAP (transversus abdominis plane) block or QL (quadratus lumborum) block is an effective alternative for abdominal surgery

6. Induction of Anaesthesia

Premedication

• Anxiolytic (oral midazolam) - use cautiously and in reduced dose (prolonged effect due to reduced protein binding and impaired metabolism in jaundiced patients)
• H2 blocker/PPI + metoclopramide (aspiration prophylaxis)
• Antifibrinolytics: Tranexamic acid 1 g IV at induction if major bleeding expected

Induction Agents

• Propofol (preferred) - highly lipophilic, high extraction ratio; clearance relatively preserved in jaundice without cirrhosis; use reduced dose due to hypoalbuminaemia (increased free fraction)
• Thiopentone - alternative; pharmacodynamic effects more pronounced
• Ketamine - useful if haemodynamically compromised (but avoid in raised ICP/tachycardia)
• Etomidate - preferred if cardiovascular instability (minimal cardiac depression)

Rapid Sequence Induction (RSI)

• Consider RSI if gastric emptying is delayed (periampullary malignancy) or if ascites is present
• Pre-oxygenation with 100% O2 for 3 minutes
• Cricoid pressure while airway secured

Neuromuscular Blockade

• Atracurium or cisatracurium: DRUGS OF CHOICE in jaundice/liver disease
  • Hoffman elimination + ester hydrolysis = organ-independent elimination
  • Duration unaffected by liver disease
  • Laudanosine (metabolite) is hepatically cleared but neurotoxicity not clinically significant
• Avoid vecuronium and rocuronium as sole agents - prolonged duration due to reduced hepatic clearance and increased volume of distribution
• Avoid succinylcholine if suspecting plasma cholinesterase deficiency (reduced in liver disease)

Intubation

• Rapid sequence with RSI if risk factors present
• Standard orotracheal intubation otherwise
• Thoracic epidural placed prior to induction (or post-induction in anaesthetised patient at T6-T8)

7. Intraoperative Monitoring

• ECG (5-lead), SpO2, ETCO2, temperature
• Urine output (Foley catheter - target ≥0.5 mL/kg/h)

• Arterial line (radial artery) - beat-to-beat BP monitoring; frequent ABG and blood sampling; assessment of pulse pressure variation (PPV) for fluid responsiveness
• Central venous catheter - CVP guidance; vasoactive drug infusion; avoid left internal jugular vein if venous resection/reconstruction anticipated (IJV may be needed as vascular conduit)
• Cardiac output monitoring (FloTrac/Vigileo, LIDCO, oesophageal Doppler) - goal-directed fluid therapy in long procedures
• BIS/depth of anaesthesia monitor - avoid awareness (particularly important with reduced drug requirements in jaundice)
• Blood glucose monitoring - hourly; target 6-10 mmol/L
• Temperature monitoring - active warming (Bair Hugger); hypothermia worsens coagulopathy
• Neurological (if epidural) - test dose before activation; monitor for local anaesthetic toxicity

8. Maintenance of Anaesthesia

Volatile Agents

• Isoflurane or Sevoflurane: agents of choice in patients with liver disease
  • At 1 MAC: minimal reduction of hepatic blood flow
  • Maintain hepatic arterial buffer response
  • Sevoflurane: dose-dependent reduction does NOT occur at higher MAC (safest)
  • Isoflurane: minimal TFA (trifluoroacetate) production (0.2% metabolised vs 20% halothane)
• Avoid Halothane: greatest cardiovascular depression, maximal hepatic blood flow reduction, risk of halothane hepatitis
• Desflurane: 30% reduction in hepatic blood flow at 1 MAC - less preferred
• Nitrous oxide: avoid due to bowel distension and impaired gut healing

Key Intraoperative Goals

• Maintain normotension (MAP >65 mmHg): hypotension reduces hepatic blood flow and precipitates HRS
• Avoid excessive sympathetic activation (light anaesthesia, pain, laryngospasm)
• Avoid high mean airway pressures: reduces hepatic venous outflow
• Normoventilation (avoid hypercapnia and hyperventilation)

Opioids

• Fentanyl (intraoperative): short-acting; redistribution governs single-dose elimination
• Remifentanil infusion: ideal in jaundice - eliminated by blood and tissue esterases, completely independent of hepatic function regardless of infusion duration
• Morphine and meperidine: avoid or use with extreme caution - prolonged elimination in liver disease; normeperidine accumulation = neurotoxicity
• Reduce all opioid doses due to pharmacodynamic sensitivity (increased CNS sensitivity, risk of precipitating encephalopathy)

Fluid Management (Goal-Directed)

• Balanced crystalloids (Hartmann's/Plasmalyte) as maintenance
• Albumin infusions if serum albumin <25 g/L (especially after large fluid shifts intraoperatively)
• Blood products guided by POC coagulation testing (TEG/ROTEM preferred over standard PT/INR in the operating room - gives real-time assessment of coagulation status)
• Avoid overhydration: worsens bowel oedema and anastomotic healing
• Avoid underhydration: precipitates HRS, AKI
• Target CVP 5-8 mmHg during resection phase, allow higher during reconstruction
• Mannitol 0.5 g/kg given at start of surgery - renal protection from hepatorenal syndrome risk
• Cell salvage device on standby

Vasopressors

• Jaundiced patients have reduced response to vasoconstrictors (vasoplegia from nitric oxide, prostacyclin)
• Noradrenaline (norepinephrine): first-line vasopressor
• Vasopressin: useful adjunct, promotes renal perfusion
• Note: catecholamines may paradoxically reduce hepatic blood flow via hepatic arterial vasoconstriction

9. Regional Anaesthesia Considerations

Thoracic Epidural Analgesia (TEA) - T6-T8

• Placed pre-induction or post-induction
• Test dose: 3 mL lignocaine 2% with adrenaline 1:200,000 (checks for IV or intrathecal placement)
• Maintenance: bupivacaine 0.1-0.125% + fentanyl 2 mcg/mL at 6-12 mL/hr OR PCEA (patient-controlled epidural analgesia)
• Monitor: sensory block level, BP, HR, motor block in lower limbs
• Prerequisite: INR <1.5, platelets >80,000 before placement

Alternatives if Epidural Contraindicated

• TAP block (transversus abdominis plane): bilateral ultrasound-guided; effective for anterior abdominal wall pain (T10-L1)
• Quadratus Lumborum (QL) block: wider coverage (T7-L1), increasingly used for hepatopancreatic surgery
• IV ketamine infusion (sub-anaesthetic dose 0.1-0.3 mg/kg/h): opioid-sparing, prevents central sensitisation
• Multimodal analgesia: paracetamol (caution in hepatic impairment; reduce dose), avoid NSAIDs (renal risk + platelet dysfunction)

10. Extubation and Recovery

• Criteria for extubation on table: haemodynamically stable, normothermic, coagulation corrected, responsive, adequate respiratory effort, ETCo2 normal
• If prolonged surgery (>6 hours), massive transfusion, or haemodynamic instability - planned elective ventilation in ICU
• Reverse neuromuscular blockade: neostigmine + glycopyrrolate (or sugammadex if rocuronium used)
• Adequate analgesia confirmed before extubation (check epidural function)
• ICU/HDU admission: all patients post-Whipple require at least 24-48 hours high-dependency monitoring

11. Postoperative Anaesthetic Management

Pain

• Continue TEA for 3-5 days postoperatively (PCEA most effective)
• Step down to oral multimodal analgesia (paracetamol ± tramadol ± NSAIDs - NSAIDs cautiously only once renal function confirmed stable)
• Avoid excessive opioids: risk of respiratory depression, ileus, encephalopathy

Postoperative Renal Protection

• Maintain urine output ≥0.5 mL/kg/h
• Daily creatinine monitoring
• Avoid nephrotoxins (aminoglycosides, NSAIDs)
• Consider mannitol or frusemide if oliguria develops

Glucose Management

• Postoperative hyperglycaemia common (pancreatic head resection disrupts insulin secretion)
• Insulin sliding scale or infusion; target 6-10 mmol/L
• Risk of hypoglycaemia after total pancreatectomy (absent glucagon)

ICU Monitoring

• Hourly urine output, 4-hourly blood glucose
• Daily LFTs, coagulation profile, electrolytes
• Drain output (amylase on POD 3 for CR-POPF screening)
• DVT prophylaxis: LMWH + compression stockings once haemostasis confirmed

12. Specific Anaesthetic Risks in This Setting

13. ERAS Protocol for Whipple Surgery (Anaesthetic Components)

• No prolonged fasting (clear fluids up to 2 hours; carbohydrate loading 6 hours before)
• Avoid routine bowel preparation
• Thoracic epidural placement
• Goal-directed fluid therapy (avoid over-hydration)
• Opioid-minimising multimodal analgesia
• Early extubation (avoid prolonged ventilation)
• Postoperative nausea and vomiting (PONV) prophylaxis (ondansetron + dexamethasone - caution with dexamethasone in diabetics)
• Early nasogastric removal and early oral intake
• DVT prophylaxis from day 0

Summary for Exam